Aclidinium bromide inhibits proliferation of osteosarcoma cells through regulation of PI3K/Akt pathway.
CONCLUSIONS: Therefore, the current study reveals that aclidinium bromide might inhibit osteosarcoma cell growth by regulating the PI3K/AKT signaling pathway, which suggests aclidinium bromide is a potential chemotherapeutic agent for osteosarcoma.
PMID: 30657552 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
More News: Aclidinium Bromide | Bone Cancers | Brain Tumor | Cancer | Cancer & Oncology | Carcinoma | Colon Cancer | Colorectal Cancer | Drugs & Pharmacology | Gastric (Stomach) Cancer | Gastroenterology | Glioma | Osteosarcoma | Ovarian Cancer | Ovaries | Study | Toxicology